Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 17 November 2015 | By Zachary Brennan
The US Food and Drug Administration (FDA) on Wednesday plans to release finalized guidance on formal meetings between FDA and biosimilar sponsors.
The agency said that as a result of the public comments on the draft guidance from April 2013, information has been added “to provide clarity on the process for requesting meetings, including identifying the appropriate meeting type and the data expectations to support the appropriate meeting type.”
The Generic Pharmaceutical Association (GPhA) previously called for FDA to specify which electronic Common Technical Document (eCTD) submission format it would accept and what needed to be included on the eCTD.
The guidance addresses five types of meetings between the agency and biosimilar sponsors: (1) Biosimilar Initial Advisory meeting; (2) Biosimilar Product Development (BPD) Type 1 meeting; (3) BPD Type 2 meeting; (4) BPD Type 3 meeting; and (5) BPD Type 4 meeting.
“The good meeting management practices in this guidance are intended to provide consistent procedures that will promote well-managed meetings and to ensure that such meetings are scheduled within a reasonable time, conducted efficiently, and documented appropriately,” FDA said.
FDA is supposed to hold meetings within 30, 75, 120 and 60 days for BPD Type 1, 2, 3 and 4 requests, respectively.
All BPD meetings are subject to user fees, while the initial advisory meetings are exempt. There are three types of BPD fees: an initial fee, an annual fee and a reactivation fee if a product has since dropped out of the regulatory review process. Fees for the initial BPD meeting must be paid within five days of the meeting request being granted or else the meeting may be canceled.
The guidance also explains procedures for the content of meeting request submissions, the approval or denial of those submissions, conduct during the meetings and disputes regarding meeting minutes.
Tags: biosimilars, biosimilars guidance, GPhA, BPD, biosimilars meetings